Cantor Fitzgerald analyst Alethia Young expects shares of Agios Pharmaceuticals to trade up 5%-10% after the company announced initial "positive" topline Phase 2 proof of concept data for mitapivat in thalassemia. The biggest investor pushback on the mitapivat program has been the size of the market opportunity, Young tells investors in a research note. The analyst, who thinks investors currently give little credit to expansion opportunities in thalassemia and sickle cell disease, believes the efficacy on mitapivat "looks promising" in the cohort of 12 patients based on hemoglobin increases. Young reiterates an Overweight rating on Agios Pharmaceuticals with a $64 price target.